Zydus Lifesciences gets warning letter from USFDA for its Jarod injectable unit

Zydus Lifesciences received a warning letter from the USFDA regarding its injectables manufacturing facility at Jarod, following an inspection in April 2024. The letter cites violations of cGMP regulations. Zydus must respond within 15 days and take remedial action. The warning limits new product launches, impacting business growth in the US market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Ufi6SM5
via IFTTT